SML0148
Imidapril hydrochloride
≥98% (HPLC)
别名:
(4S)-3-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-4-imidazolidinecarboxylic acid hydrochloride, Novaloc, TA 6366, Tanapril
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C20H27N3O6 · HCl
化学文摘社编号:
分子量:
441.91
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77
方案
≥98% (HPLC)
表单
powder
旋光性
[α]/D -50 to -70° in ethanol (c=0.5)
颜色
white to tan
溶解性
H2O: ≥5 mg/mL
创始人
Trinity Pharma Solutions
储存温度
−20°C
SMILES字符串
Cl.CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2[C@@H](CN(C)C2=O)C(O)=O
InChI
1S/C20H27N3O6.ClH/c1-4-29-19(27)15(11-10-14-8-6-5-7-9-14)21-13(2)17(24)23-16(18(25)26)12-22(3)20(23)28;/h5-9,13,15-16,21H,4,10-12H2,1-3H3,(H,25,26);1H/t13-,15-,16-;/m0./s1
InChI key
LSLQGMMMRMDXHN-GEUPQXMHSA-N
一般描述
Imidapril comprises large acyl moiety and is hydrolyzed by carboxylesterase (CES) 1.
应用
Imidapril hydrochloride may be used to test its effect on pharyngeal and laryngeal muscle to treat impaired swallowing.
Imidapril hydrochloride was used as a standard in bioequivalence test by LC/MS method.
生化/生理作用
Angiotensin Converting Enzyme (ACE) inhibitor
Imidapril hydrochloride is a long-acting inhibitor of angiotensin converting enzyme used in the treatment of hypertension, congestive heart failure and diabetic nephropathy. It restores decreased airway sensation and bladder sensation in patients with multiple sclerosis.
Imidapril is a potent angiotensin converting enzyme inhibitor and anti-hypertensive.
特点和优势
This compound is featured on the Angiotensin Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Trinity Pharma Solutions. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
此项目有
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
Roberto Fogari et al.
Hypertension research : official journal of the Japanese Society of Hypertension, 34(12), 1321-1326 (2011-08-05)
To evaluate the relationship between plasma plasminogen activator inhibitor-1 (PAI-1) and angiotensin II (Ang II) changes during treatment with imidapril and candesartan in hypertensive patients with metabolic syndrome. A total of 84 hypertensive patients with metabolic syndrome were randomized to
Imidapril, an angiotensin-converting enzyme inhibitor, can reverse loss of bladder sensation.
R Sakakibara et al.
Journal of neurology, neurosurgery, and psychiatry, 77(9), 1100-1101 (2006-08-18)
Mitsuru Ohishi et al.
Hypertension research : official journal of the Japanese Society of Hypertension, 33(11), 1150-1154 (2010-08-13)
The principal means for reducing proteinuria in patients with chronic kidney disease are strong blockade of the renin-angiotensin system and strict regulation of blood pressure (BP). This study compared the efficacy of the maximum permissible doses of two common angiotensin
Yi-Fei Dong et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 25(9), 2911-2920 (2011-05-20)
The purpose of this work was to test whether brain-penetrating angiotensin-converting enzyme (ACE) inhibitors (e.g., perindopril), as opposed to non-brain-penetrating ACE inhibitors (e.g., enalapril and imidapril), may reduce the cognitive decline and brain injury in Alzheimer's disease (AD). We first
Roberto Fogari et al.
Hypertension research : official journal of the Japanese Society of Hypertension, 34(4), 509-515 (2010-12-24)
The aim of this study was to evaluate the effects of imidapril and candesartan on fibrinolysis and insulin sensitivity in normoweight hypertensive patients. After a 2-week wash-out period, 61 patients with mild-to-moderate hypertension were randomized to imidapril or candesartan for
商品
We offer many products related to angiotensin receptors for your research needs.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持